Simulations Plus, Inc (SLP)

Etorro trading 970x250
Simulations Plus, Inc (SLP) Logo

About Simulations Plus, Inc

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California. Address: 42505 Tenth Street West, Lancaster, CA, United States, 93534-7059

Simulations Plus, Inc News and around…

Latest news about Simulations Plus, Inc (SLP) common stock and company :

Is Simulations Plus, Inc. (NASDAQ:SLP) Worth US$40.9 Based On Its Intrinsic Value?
10 May, 2022 Yahoo! Finance

Today we will run through one way of estimating the intrinsic value of Simulations Plus, Inc. ( NASDAQ:SLP ) by...

Add Up The Pieces: SLYV Could Be Worth $99
06 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P 600 Small Cap Value ETF (SLYV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $99.47 per unit.

U.S. FDA Renews Annual DILIsym Software Licenses for 2022
05 May, 2022 FinancialContent

Simulations Plus announced the FDA renewed annual licenses to DILIsym, the DILIsym division's QST software for predicting drug-induced liver injury.

Simulations Plus Successfully Delivers FDA-Funded Project
28 Apr, 2022 FinancialContent

Simulations Plus successfully establishes the suitability of model-integrated evidence for BE studies of LAI drug products in FDA-funded project.

Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
21 Apr, 2022 FinancialContent

Simulations Plus entered a funded collaboration to advance innovative IVIVE methods for dissolution and precipitation modeling in its DDDPlus software

Simulations Plus to Present at the Berenberg Discover AI Seminar
19 Apr, 2022 FinancialContent

Shawn O'Connor, chief executive officer of Simulations Plus, will be presenting at the Berenberg Discover AI Seminar in Boston, on April 26, 2022.

Can Simulations Plus Stock Maintain Its Impressive Growth?
15 Apr, 2022 FinancialContent

Simulations Plus, Inc. held up well in the company’s recently released financial results.

Simulations Plus (SLP) Q2 Earnings Top Estimates, Revenues Up
11 Apr, 2022 Yahoo! Finance

Simulations Plus (SLP) Q2 results benefit from strength in the Software business. However, a decline in Services revenues acted as a headwind.

Simulations Plus: Q2 Earnings Insights
07 Apr, 2022 FinancialContent

Simulations Plus (NASDAQ:SLP) reported its Q2 earnings results on Wednesday, April 6, 2022 at 04:05 PM. Here's what ...

Simulations Plus, Inc. (SLP) Q2 2022 Earnings Call Transcript
07 Apr, 2022 FinancialContent

SLP earnings call for the period ending March 31, 2022.

Simulations Plus (SLP) Surpasses Q2 Earnings Estimates
06 Apr, 2022 Yahoo! Finance

Simulations Plus (SLP) delivered earnings and revenue surprises of 50% and 1.55%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
06 Apr, 2022 FinancialContent

Simulations Plus reports total revenue of $14.8 million, up 13%, for the 2nd quarter of FY22 with software revenue growth of 25%, to $9.8 million.

Earnings Preview For Simulations Plus
05 Apr, 2022 FinancialContent

Simulations Plus (NASDAQ:SLP) is set to give its latest quarterly earnings report on Wednesday, 2022-04-06. Here's what investors need ...

Sylvania Platinum (LON:SLP) Knows How To Allocate Capital Effectively
01 Apr, 2022 Yahoo! Finance

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...

Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
29 Mar, 2022 FinancialContent

Simulations Plus will partner with the University of Pittsburgh to develop and validate its novel BIOLOGXsym QST software with funding from the NIH.

Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
24 Mar, 2022 FinancialContent

Simulations Plus hosted its 2022 MIDD+ Scientific Conference on Feb. 16-17, 2022, with speakers from the US FDA, ANVISA, Health Canada, & MHRA-UK.

Why Are Axie Infinity (AXS) And Smooth Love Potion (SLP) Tokens Soaring Today?
24 Mar, 2022 FinancialContent

Axie Infinity (AXS) and Smooth Love Potion (SLP) — tokens attached to the popular non fungible token (NFT) game are ...

Sum Up The Pieces: SLYV Could Be Worth $101
23 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P 600 Small Cap Value ETF (SLYV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $100.73 per unit.

Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call
22 Mar, 2022 FinancialContent

Simulations Plus announced today that it will report 2nd quarter fiscal year 2022 financial results on Wed., April 6, 2022, with a webcast at 5pm ET.

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders
17 Mar, 2022 FinancialContent

Simulations Plus donates $25,000 to the National Organization for Rare Disorders, an advocacy organization devoted to individuals with rare diseases.

Should Weakness in Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
15 Mar, 2022 Yahoo! Finance

With its stock down 16% over the past three months, it is easy to disregard Simulations Plus (NASDAQ:SLP). However, the...

Asure Software Inc (ASUR) Q4 Earnings and Revenues Top Estimates
14 Mar, 2022 Yahoo! Finance

Asure Software Inc (ASUR) delivered earnings and revenue surprises of 150% and 0.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus Releases MembranePlus 3.0
10 Mar, 2022 FinancialContent

Simulations Plus today announced the release of MembranePlus 3.0, the company's mechanistic in vitro permeability & hepatocyte modeling software.

Simulations Plus to Present at Oppenheimer Annual Healthcare Conference
08 Mar, 2022 FinancialContent

Simulations Plus CEO Shawn O'Connor will be presenting and hosting 1-1 meetings on March 15, 2022, at Oppenheimer's 32nd Annual Healthcare Conference.

Is Simulations Plus (SLP) A Great Investment Pick?
07 Mar, 2022 Yahoo! Finance

Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly net return of 2.86% was recorded by the fund for the fourth quarter of 2021, beating its Benchmark, the MSCI All Country World Small Cap Index, […]

Simulations Plus to Present at Raymond James Institutional Investors Conference
02 Mar, 2022 FinancialContent

Simulations Plus CEO Shawn O'Connor will be presenting on March 9, 2022, at the Raymond James Institutional Investors Conference in Orlando, Florida.

Implied IJR Analyst Target Price: $135
16 Feb, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Small-Cap ETF (IJR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $134.59 per unit.

Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
08 Feb, 2022 FinancialContent

Simulations Plus CEO Shawn O'Connor will be presenting on Feb 15, 2022, at BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Why Metaverse Cryptocurrency Axie Infinity Is Soaring Today
05 Feb, 2022 FinancialContent

This cryptocurrency is climbing higher alongside the broader market.

Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
20 Jan, 2022 FinancialContent

Simulations Plus enters another new funded collaboration to enhance GastroPlus and advance research into new treatments for gastrointestinal diseases.

Simulations Plus, Inc (SLP) is a NASDAQ Common Stock listed in , ,

970x250